ADTX Market Analysis

Overview

Fundamentals

P/E ratioForward 0.35
EPS (TTM)$-1,380.800.0% YoY
Profit margin0.0%HEALTHCARE
Market cap$3590Micro cap

Valuation

Forward P/E
0.35
PEG ratio
P/B
0.05
P/S (TTM)
0.25
EV/EBITDA
0.02

Profitability & growth

ROE (TTM)
-699.0%
Operating margin
-35874.0%
Revenue growth YoY
1094.0%
Dividend yield
Beta
-17.50
Last earnings
Nov 17, 2025 · Estimate $0.00 · Reported $-548.78
Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Aditxt Inc.

Aditxt Inc. is an innovative biotechnology company dedicated to transforming healthcare through its proprietary immune modulation and personalized medicine platform. Focused on enhancing immune responses to address chronic diseases and allergies, Aditxt aims to significantly improve patient outcomes. With a robust pipeline of therapeutic candidates supported by comprehensive research and strategic collaborations, the company is poised to be a leader in the rapidly evolving field of immune-based therapies. Aditxt's commitment to scientific advancement and patient-centric solutions positions it…

Classification

Exchange
NASDAQ
Country
USA
Currency
USD

Company profile

HQ
2569 WYANDOTTE STREET, MOUNTAIN VIEW, CA
Fiscal year end
December
Latest quarter
Mar 31, 2026
Market cap$3590
Shares outstanding$815920
52W high$53,453.52
52W low$0.00

We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer